miR-5000-3p, miR-5009-3P and miR-552: Potential microRNA biomarkers of side population cells in colon cancer

Xia,Zhong-Sheng; Wang,Lin; Yu,Tao; Zhong,Wa; Lian,Guo-Da; Wu,Di; Zhou,Hui-Min; Chen,Guang-Cheng

doi:10.3892/or.2014.3232

miR-5000-3p, miR-5009-3P and miR-552: Potential microRNA biomarkers of side population cells in colon cancer

Authors:
- Zhong-Sheng Xia
- Lin Wang
- Tao Yu
- Wa Zhong
- Guo-Da Lian
- Di Wu
- Hui-Min Zhou
- Guang-Cheng Chen
View Affiliations

Affiliations: Department of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China, Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, P.R. China
Published online on: June 4, 2014 https://doi.org/10.3892/or.2014.3232
Pages: 589-596

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colon cancer is one of the most common cancers in the world. Multidrug resistance is related to poor prognosis of advanced colon cancer. The side population plays an important role in multiple drug resistance (MDR) of colon cancer. MicroRNA biomarkers of the side population of colon cancer is still unknown. In the present study, we aimed to explore miRNA markers of side population (SP) cells of colon cancer. The side population was sorted by flow cytometry. Cell viability was measured using an MTT assay. MicroRNA profiling analysis was performed to compare microRNA expression levels in the SP cells of colon cancer with levels in the non-SP cells of colon cancer. RT-PCR was applied to verify the result obtained from the microRNA profiling analysis. miR-5000-3p, miR-5009-3P and miR-552 were all found to be upregulated in SP cells of the colon cancer cell lines HCT-15, HT-29 and LoVo. RT-PCR confirmed the result from the microRNA profiling analysis. This implied that miR-5000-3p, miR-5009-3P and miR-552 may be potential microRNA biomarkers of the side population in colon cancer, which may provide new specific targets of the side population for the reversal of MDR of colon cancer.

View Figures

View References

1	Hawk ET, Limburg PJ and Viner JL: Epidemiology and prevention of colorectal cancer. Surg Clin North Am. 82:905–941. 2002. View Article : Google Scholar : PubMed/NCBI
2	Sung J: Does fecal occult blood test have a place for colorectal cancer screening in China in 2006? Am J Gastroenterol. 101:213–215. 2006. View Article : Google Scholar : PubMed/NCBI
3	Taal BG, Van Tinteren H and Zoetmulder FA: Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer. 85:1437–1443. 2001. View Article : Google Scholar : PubMed/NCBI
4	Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 355:1041–1047. 2000. View Article : Google Scholar
5	Redmond SM, Joncourt F, Buser K, et al: Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O⁶-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res. 51:2092–2097. 1991.PubMed/NCBI
6	van den Heuvel-Eibrink MM, Sonneveld P and Pieters R: The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther. 38:94–110. 2000.PubMed/NCBI
7	Tsuruo T, lida H, Tsukagoshi S, et al: Overcoming of vincristine resistence in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967–1972. 1981.PubMed/NCBI
8	Gao Z, Fields JZ and Boman BM: Co-transfection of MDR1 and MRP antisense RNAs abolishes the drug resistance in multidrug resistant human lung cancer cells. Anticancer Res. 18:3073–3076. 1998.PubMed/NCBI
9	Xia Z, Zhu Z, Zhang L, et al: Specific reversal of MDR1/P-gp-dependent multidrug resistance by RNA interference in colon cancer cells. Oncol Rep. 20:1433–1439. 2008.PubMed/NCBI
10	Todaro M, Francipane MG, Medema JP and Stassi G: Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 138:2151–2162. 2010. View Article : Google Scholar : PubMed/NCBI
11	Todaro M, Alea Mp, Di Stefano AB, et al: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 1:389–402. 2007. View Article : Google Scholar : PubMed/NCBI
12	Lee CJ, Dosch J and Simeone DM: Pancreatic cancer stem cells. J Clin Oncol. 26:2806–2812. 2008. View Article : Google Scholar : PubMed/NCBI
13	Zheng X, Shen G, Yang X and Liu W: Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res. 67:3691–3697. 2007. View Article : Google Scholar : PubMed/NCBI
14	Beier D, Hau P, Proescholdt M, et al: CD133⁺ and CD133⁻ glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:4010–4015. 2007.PubMed/NCBI
15	Sakariassen PØ, Immervoll H and Chekenya M: Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia. 9:882–892. 2007.PubMed/NCBI
16	Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al: Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA. 103:11154–11159. 2006. View Article : Google Scholar : PubMed/NCBI
17	Hirschmann-Jax C, Foster AE, Wulf GG, et al: A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 101:14228–14233. 2004.
18	Zhou S, Schuetz JD, Bunting KD, et al: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
19	Behbod F, Xian W, Shaw CA, et al: Transcriptional profiling of mammary gland side population cells. Stem Cells. 24:1065–1074. 2006. View Article : Google Scholar : PubMed/NCBI
20	Goodell MA, Brose K, Paradis G, et al: Isolation and functional propertied of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 183:1797–1806. 1996. View Article : Google Scholar : PubMed/NCBI
21	Carmichael J, Degraff WG, Gazdar AF, et al: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI
22	Murase M, Kano M, Tsukahara T, et al: Side population cells have the characteristics of cancer stem-like cellscancer-initiating cells in bone sarcomas. Br J Cancer. 101:1425–1432. 2009. View Article : Google Scholar : PubMed/NCBI
23	Kondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA. 101:781–786. 2004. View Article : Google Scholar : PubMed/NCBI
24	Chiba T, Kita K, Zheng YW, et al: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 44:240–251. 2006. View Article : Google Scholar : PubMed/NCBI
25	Ho MM, Ng AV, Lam S and Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67:4827–4833. 2007. View Article : Google Scholar : PubMed/NCBI
26	Mitsutake N, Iwao A, Nagai K, et al: Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology. 148:1797–1803. 2007. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Guo LP, Chen LZ, et al: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 67:3716–3724. 2007. View Article : Google Scholar : PubMed/NCBI
28	Haraguchi N, Utsunomiya T, Inoue H, et al: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 24:506–513. 2006. View Article : Google Scholar : PubMed/NCBI
29	Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 299:425–436. 2008. View Article : Google Scholar : PubMed/NCBI
30	Callari M, Dugo M, Musella V, et al: Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues. PLoS One. 7:1–15. 2012. View Article : Google Scholar
31	Inoda S, Hirohashi Y, Torigoe T, et al: Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol. 178:1805–1813. 2011. View Article : Google Scholar : PubMed/NCBI
32	Link A, Balaguer F, Shen Y, et al: Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 19:1766–1774. 2010. View Article : Google Scholar : PubMed/NCBI
33	Hofsli E, Sjursen W, Prestvik WS, et al: Identification of serum microRNA profiles in colon cancer. Br J Cancer. 108:1712–1719. 2013. View Article : Google Scholar : PubMed/NCBI
34	Zhang H, Li W, Nan F, et al: MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line. Biochem Biophys Res Commun. 404:273–278. 2011. View Article : Google Scholar : PubMed/NCBI
35	Fang Y, Xiang J, Chen ZY, et al: miRNA expression profile of colon cancer stem cells compared to non-stem cells using the SW1116 cell line. Oncol Rep. 28:2115–2124. 2012.PubMed/NCBI